![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RALA |
Gene summary for RALA |
![]() |
Gene information | Species | Human | Gene symbol | RALA | Gene ID | 5898 |
Gene name | RAS like proto-oncogene A | |
Gene Alias | HINCONS | |
Cytomap | 7p14.1 | |
Gene Type | protein-coding | GO ID | GO:0000266 | UniProtAcc | P11233 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5898 | RALA | LN22 | Human | Oral cavity | OSCC | 7.46e-04 | 8.58e-01 | 0.1733 |
5898 | RALA | LN38 | Human | Oral cavity | OSCC | 2.89e-04 | 1.21e+00 | 0.168 |
5898 | RALA | LN46 | Human | Oral cavity | OSCC | 1.70e-39 | 1.47e+00 | 0.1666 |
5898 | RALA | LP15 | Human | Oral cavity | LP | 1.42e-11 | 2.08e+00 | 0.2174 |
5898 | RALA | LP17 | Human | Oral cavity | LP | 1.94e-06 | 1.25e+00 | 0.2349 |
5898 | RALA | EOLP-1 | Human | Oral cavity | EOLP | 2.56e-04 | 3.54e-01 | -0.0202 |
5898 | RALA | SYSMH1 | Human | Oral cavity | OSCC | 1.49e-34 | 9.67e-01 | 0.1127 |
5898 | RALA | SYSMH2 | Human | Oral cavity | OSCC | 5.89e-31 | 1.16e+00 | 0.2326 |
5898 | RALA | SYSMH3 | Human | Oral cavity | OSCC | 1.52e-32 | 1.21e+00 | 0.2442 |
5898 | RALA | SYSMH4 | Human | Oral cavity | OSCC | 3.10e-03 | 1.74e-01 | 0.1226 |
5898 | RALA | SYSMH5 | Human | Oral cavity | OSCC | 1.86e-13 | 7.35e-01 | 0.0647 |
5898 | RALA | SYSMH6 | Human | Oral cavity | OSCC | 2.97e-06 | 6.10e-01 | 0.1275 |
5898 | RALA | P4_S8_cSCC | Human | Skin | cSCC | 1.04e-07 | 1.49e-01 | -0.3095 |
5898 | RALA | P5_S10_cSCC | Human | Skin | cSCC | 2.31e-25 | 3.70e-01 | -0.299 |
5898 | RALA | P1_cSCC | Human | Skin | cSCC | 3.99e-36 | 1.14e+00 | 0.0292 |
5898 | RALA | P2_cSCC | Human | Skin | cSCC | 3.00e-09 | 5.65e-01 | -0.024 |
5898 | RALA | P4_cSCC | Human | Skin | cSCC | 8.19e-30 | 9.29e-01 | -0.00290000000000005 |
5898 | RALA | P10_cSCC | Human | Skin | cSCC | 2.42e-31 | 1.42e+00 | 0.1017 |
5898 | RALA | cSCC_p9 | Human | Skin | cSCC | 6.30e-03 | -2.97e-02 | -0.1991 |
5898 | RALA | male-WTA | Human | Thyroid | PTC | 4.19e-21 | 1.10e-01 | 0.1037 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007259420 | Esophagus | HGIN | establishment of protein localization to organelle | 120/2587 | 422/18723 | 1.73e-15 | 4.00e-13 | 120 |
GO:007058520 | Esophagus | HGIN | protein localization to mitochondrion | 43/2587 | 125/18723 | 4.43e-09 | 3.03e-07 | 43 |
GO:007265520 | Esophagus | HGIN | establishment of protein localization to mitochondrion | 41/2587 | 120/18723 | 1.26e-08 | 7.96e-07 | 41 |
GO:001082119 | Esophagus | HGIN | regulation of mitochondrion organization | 42/2587 | 144/18723 | 1.20e-06 | 4.68e-05 | 42 |
GO:00108228 | Esophagus | HGIN | positive regulation of mitochondrion organization | 20/2587 | 74/18723 | 2.00e-03 | 2.12e-02 | 20 |
GO:00018438 | Esophagus | HGIN | neural tube closure | 22/2587 | 88/18723 | 3.57e-03 | 3.27e-02 | 22 |
GO:00018389 | Esophagus | HGIN | embryonic epithelial tube formation | 28/2587 | 121/18723 | 3.72e-03 | 3.39e-02 | 28 |
GO:00140209 | Esophagus | HGIN | primary neural tube formation | 23/2587 | 94/18723 | 3.92e-03 | 3.54e-02 | 23 |
GO:00606067 | Esophagus | HGIN | tube closure | 22/2587 | 89/18723 | 4.14e-03 | 3.70e-02 | 22 |
GO:000184114 | Esophagus | HGIN | neural tube formation | 24/2587 | 102/18723 | 5.54e-03 | 4.52e-02 | 24 |
GO:006049117 | Esophagus | HGIN | regulation of cell projection assembly | 39/2587 | 188/18723 | 5.61e-03 | 4.57e-02 | 39 |
GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
GO:0072655110 | Esophagus | ESCC | establishment of protein localization to mitochondrion | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
GO:0070585110 | Esophagus | ESCC | protein localization to mitochondrion | 100/8552 | 125/18723 | 2.96e-15 | 1.77e-13 | 100 |
GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
GO:0010821110 | Esophagus | ESCC | regulation of mitochondrion organization | 107/8552 | 144/18723 | 2.31e-12 | 9.41e-11 | 107 |
GO:001082215 | Esophagus | ESCC | positive regulation of mitochondrion organization | 58/8552 | 74/18723 | 8.55e-09 | 1.73e-07 | 58 |
GO:000184115 | Esophagus | ESCC | neural tube formation | 75/8552 | 102/18723 | 9.68e-09 | 1.95e-07 | 75 |
GO:000184314 | Esophagus | ESCC | neural tube closure | 66/8552 | 88/18723 | 1.98e-08 | 3.82e-07 | 66 |
GO:001402014 | Esophagus | ESCC | primary neural tube formation | 69/8552 | 94/18723 | 4.22e-08 | 7.76e-07 | 69 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513239 | Esophagus | HGIN | Salmonella infection | 69/1383 | 249/8465 | 3.02e-06 | 4.47e-05 | 3.55e-05 | 69 |
hsa05132115 | Esophagus | HGIN | Salmonella infection | 69/1383 | 249/8465 | 3.02e-06 | 4.47e-05 | 3.55e-05 | 69 |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0521020 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
hsa0521216 | Esophagus | ESCC | Pancreatic cancer | 62/4205 | 76/8465 | 7.37e-09 | 6.85e-08 | 3.51e-08 | 62 |
hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa05210110 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
hsa0521217 | Esophagus | ESCC | Pancreatic cancer | 62/4205 | 76/8465 | 7.37e-09 | 6.85e-08 | 3.51e-08 | 62 |
hsa0513214 | Liver | NAFLD | Salmonella infection | 55/1043 | 249/8465 | 8.48e-06 | 3.09e-04 | 2.49e-04 | 55 |
hsa0513215 | Liver | NAFLD | Salmonella infection | 55/1043 | 249/8465 | 8.48e-06 | 3.09e-04 | 2.49e-04 | 55 |
hsa0513222 | Liver | Cirrhotic | Salmonella infection | 121/2530 | 249/8465 | 2.47e-10 | 5.13e-09 | 3.16e-09 | 121 |
hsa052107 | Liver | Cirrhotic | Colorectal cancer | 39/2530 | 86/8465 | 1.67e-03 | 8.01e-03 | 4.94e-03 | 39 |
hsa052126 | Liver | Cirrhotic | Pancreatic cancer | 34/2530 | 76/8465 | 4.20e-03 | 1.63e-02 | 1.00e-02 | 34 |
hsa0513232 | Liver | Cirrhotic | Salmonella infection | 121/2530 | 249/8465 | 2.47e-10 | 5.13e-09 | 3.16e-09 | 121 |
hsa0521012 | Liver | Cirrhotic | Colorectal cancer | 39/2530 | 86/8465 | 1.67e-03 | 8.01e-03 | 4.94e-03 | 39 |
hsa0521211 | Liver | Cirrhotic | Pancreatic cancer | 34/2530 | 76/8465 | 4.20e-03 | 1.63e-02 | 1.00e-02 | 34 |
hsa0513242 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
hsa0521022 | Liver | HCC | Colorectal cancer | 65/4020 | 86/8465 | 8.85e-08 | 1.23e-06 | 6.87e-07 | 65 |
hsa0521221 | Liver | HCC | Pancreatic cancer | 54/4020 | 76/8465 | 2.50e-05 | 1.64e-04 | 9.12e-05 | 54 |
hsa0513252 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RALA | SNV | Missense_Mutation | c.242N>G | p.Asn81Ser | p.N81S | P11233 | protein_coding | tolerated(0.74) | benign(0.048) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RALA | SNV | Missense_Mutation | novel | c.449A>G | p.Asn150Ser | p.N150S | P11233 | protein_coding | tolerated(0.17) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RALA | SNV | Missense_Mutation | novel | c.547A>G | p.Ser183Gly | p.S183G | P11233 | protein_coding | tolerated(0.23) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RALA | SNV | Missense_Mutation | c.421N>A | p.Glu141Lys | p.E141K | P11233 | protein_coding | tolerated(0.12) | possibly_damaging(0.562) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
RALA | SNV | Missense_Mutation | c.334N>G | p.Leu112Val | p.L112V | P11233 | protein_coding | deleterious(0.02) | possibly_damaging(0.837) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
RALA | SNV | Missense_Mutation | c.62N>C | p.Gly21Ala | p.G21A | P11233 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RALA | SNV | Missense_Mutation | c.197T>A | p.Ile66Asn | p.I66N | P11233 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RALA | SNV | Missense_Mutation | novel | c.605N>T | p.Arg202Ile | p.R202I | P11233 | protein_coding | deleterious(0.02) | possibly_damaging(0.736) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RALA | SNV | Missense_Mutation | novel | c.274N>T | p.Val92Phe | p.V92F | P11233 | protein_coding | deleterious(0.01) | probably_damaging(0.963) | TCGA-B5-A1N2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD |
RALA | SNV | Missense_Mutation | c.593N>T | p.Arg198Ile | p.R198I | P11233 | protein_coding | deleterious(0.01) | benign(0.218) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5898 | RALA | CELL SURFACE | VITAMIN E | 16861802 |
Page: 1 |